Closing Practice Gaps to
Optimize Patient Care

Login or register here.

1.5 million new chronic hepatitis B (HBV) infections are added each year. The diagnosis and management of chronic HBV are complex, but screening is step one. Our group learning workshop gives you the opportunity to interact with expert mentors and like-minded colleagues to become an HBV specialist. Learn about:
  • HBV screening, underdiagnosis, and undertreatment
  • HBV management and serology
  • Identifying and managing coinfections

How it Works
  • Four weekly video conferences with mentors and peers
  • Direct communication with an HBV expert and mentor
  • Participate in real patient cases from you and your peers and get instant feedback (discussion will be in your country’s primary language)
  • Ongoing support and mentoring from specialists
  • Earn free CME/CE for your time (please note, for those outside the US, participants should self-report. Participation certificates will be provided.)



Jointly provided by the Postgraduate Institute for Medicine and DKBmed, LLC.

Please note, for those outside the US, participants should self-report. Participation certificates will be provided.

Target Audience

This activity has been designed to meet the educational needs of healthcare providers who treat patients who have HBV or are at risk for HBV infection. This audience includes gastroenterologists, hepatologists, infectious disease specialists, HIV treaters, primary care providers, and other allied health professionals.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Detect elements of stigma toward HBV within their practice and recognize opportunities to screen patients for HBV.  
  • Assess optimal timing for care treatment among patients with HBV to minimize risk for HCC.
  • Appraise the value of emerging and available medications used to treat chronic HBV.  
  • Identify opportunities for screening patients with high risk for coinfection with HIV, HCV, or HDV.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Each webinar is applicable for 1.0 credit hour.

Nursing Continuing Professional Development

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This 1 contact hour Educational Activity is provided by the Institute for Johns Hopkins Nursing. Each webinar carries a maximum of 1 contact hour, or a total of 4 contact hours for the 4 webinars in this program. 

Media: Internet


This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty / Presenter Reported Financial Relationship

Calvin Q. Pan, MD, FACG, FAASLD

  • Grant/Research Support: Gilead Sciences, Inc.
  • Speakers Bureau/Honoraria for non-CME: Gilead Sciences, Inc.

Carla S. Coffin, MD, MSc, FRCPC

  • Grant/Research Support: Gilead Sciences, Inc., Janssen Pharmaceuticals, GlaxoSmithKline, Altimmune Pharmaceuticals
  • Consultant/Advisory Board: Altimmune Pharmaceuticals, Gilead Sciences, Inc.

David Bernstein, MACG, FAASLD, AGAF, FACP

  • Speakers Bureau/Honoraria for non-CME: Intercept
  • Consultant/Advisory Board: Ocelot Bio

Professor Teerha Piratvisuth

  • Employee/Owner: Government Officer
  • Grant/Research Support: Gilead Sciences, Inc., Roche Diagnostic, Janssen, Fibrogen, Vir Biotechnology, GlaxoSmithKline

Professor Phunchai Charatcharoenwitthaya

  • Employee/Owner: Faculty of Medicine Siriraj Hospital, Mahidol University, Mahidol University, Thailand

Toby Shu, PhD

  • None

Chen Xin, PhD Public Health

  • None

Wang Ling, MD

  • None

Planners and Managers

The PIM planners and managers have nothing to disclose. The DKBmed planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Request for Credit

There are no fees for participating and receiving CME/CE credit for this activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.

Contact Information

If you have questions regarding the certification of this activity, please contact PIM via email at [email protected]. For technical issues, please contact  [email protected]



Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
NYU Langone Health, NYU Grossman School of Medicine
New York, NY

Dr. Pan is a Professor of Medicine at the Division of Gastroenterology and Hepatology, Department of Medicine in NYU Langone Health, NYU Grossman School of Medicine in New York. Dr. Pan received his MD degree from the State University of New York in Albany and a residency at the Long Island Jewish Medical Center in New York, where he also completed a year of research fellowship in nephrology. After his Gastroenterology and Hepatology training at the Stony Brook University Hospital in New York, Dr. Pan joined the faculty at Mount Sinai School of Medicine, followed by the promotion to Assistant Professor in 2004 and Associate Professor in 2010. He then served at the Tisch Hospital of NYU School of Medicine and attained the rank of Full Professor in 2012.

Dr. Pan is an internationally recognized expert in viral hepatitis. He has devoted his career to more than 30 clinical trials in the last two decades and advancing our understanding of the natural history, prevention, and antiviral therapy for Hepatitis B or C. Among 200 plus peer-reviewed scientific papers and abstracts published, Dr. Pan was the leading author of many original articles featured in prestigious journals, including the New England Journal of Medicine, Gut, Hepatology, Journal of Hepatology, and American Journal of Gastroenterology. He also co-authored four national or international practice guidelines or consensus statements in managing viral hepatitis B, vertical transmission of hepatitis, and non-alcohol fatty liver disease. He is an associate editor for several peer-reviewed scientific journals, including the World Journal of Hepatology, Liver Research, and the Journal of Clinical and Translational Hepatology.

Besides academic work, Dr. Pan serves in a variety of leadership roles in professional organizations. He is the Chairman-elect of the Hepatitis B Special Interest Group (incoming chair of 11/2022-11/2024) in the American Association for the Study of Liver Diseases (AASLD), Past Chairman of the Online Learning Committee in AASLD (2017-19), Past Vice President of the Association of Chinese American Physicians (2010-12), and Board Member in the Political Action Committee of the American Gastroenterology Association (2019-22). He is also involved in numerous professional committees, including the International Relationship Committee of the American College of Gastroenterology (2016-19), Committee of the Coalition to Eradicate Viral Hepatitis in the Asia Pacific, Committee of the National Task Force on Hepatitis B in the US, Membership and Mentor Committee of the AASLD (2012-15), Global Engagement Committee of the AASLD (2021-23), and a role of district councilor in NY Chapter of the American College of Physicians (2019-22).

Recognized by his colleagues, Dr. Pan has received 17 accolades for his contributions to sciences and patient care. He is the recipient of the James D. Bruce Memorial Award for Distinguished Contributions in Preventive Medicine from the American College of Physicians, the Outstanding Contribution Award of the Chinese Society of Infectious Diseases, and the Certificate of Service Appreciation from the American Cancer Society. He is a Master of the American College of Physicians, Fellow of AASLD, and Fellow of the American College of Gastroenterology. As an expert and key opinion leader in his specialty, Dr. Pan serves as a keynote speaker or moderator at many international scientific congresses, expert consultant meetings of the World Health Organization, and Web-CME events.

Carla S. Coffin, MD, MSc, FRCPC

Professor of Medicine 
Cumming School of Medicine 
University of Calgary, Calgary, Alberta 

Dr. Carla S. Coffin is Professor of Medicine, Cumming School of Medicine, University of Calgary.    

Dr. Coffin received MSc degree using the woodchuck hepatitis virus model of hepatitis B with Professor Thomas I. Michalak, and MD from Memorial University.  She completed Internal Medicine and Gastroenterology at the University of Calgary, and American Association for the Study of Liver Disease (AASLD) Hepatology Fellowship with Professor Norah A. Terrault at the University of California, San Francisco.     

Dr. Coffin is a clinician scientist with a Canadian Institutes of Health Research supported research program on hepatitis B. She is leading the Canadian Hepatitis B research Network ( and co-chaired the 2018 Canadian Hepatitis B Guidelines Committee.  She is steering committee member of the AASLD Hepatitis B Special Interest Group and President-Elect of the Canadian Association for the Study of the Liver. 

David Bernstein, MD, MACG, FAASLD, AGAF, FACP
Director of Gastroenterology and Hepatology Ambulatory Network-NYU Langone Health- Long Island Professor of Medicine, NYU Langone

David E. Bernstein, MD, MACG, FAGA, FACP, FAASLD is an internationally known gastroenterologist/hepatologist. Currently, he is the Director of Gastroenterology and Hepatology Ambulatory Services -NYU Langone Health Long Island and a Professor Medicine at NYU Langone School of Medicine.    

Dr. Bernstein graduated from SUNY-Stony Brook School of Medicine, completed his medical residency at Montefiore Medical Center and his fellowship in Gastroenterology and Hepatology at the University of Miami Affiliated Hospitals. He has been the Chief of Gastroenterology for Long Island Jewish Hospital and North Shore University Hospital, and the Head of the Liver Sub-Specialty Service Line, Vice Chair of Clinical Trials, Chief, Division of Hepatology, and Director of the Sandra Atlas Bass Center for Liver Diseases for the Northwell Health System. He was a Professor of Medicine and Educational Science at the Zucker School of Medicine at Hofstra/Northwell.      

Dr. Bernstein’s research interests primarily in the management and treatment of liver diseases, with most of his work concentrated on developing new treatments for viral hepatitis, primary biliary cholangitis and fatty liver disease. He has also worked to develop new agents for procedural sedation. Dr Bernstein has authored or co-authored more than 300 original scientific manuscripts, reviews, book chapters and abstracts. He has been the principal investigator in more than 200 clinical trials.  He is a sought-after lecturer who has is invited frequently to speak at venues across the United States and around the world.     

Dr. Bernstein has been involved in shaping public policy and education regarding liver diseases in New York State. He served as a special consultant to the New York State Department of Health and in that role has helped develop and implement New York State’s 5-year Strategic Plan for Viral Hepatitis as well as work with the group developing the guidelines used for the treatment of hepatitis C in New York State.  Dr. Bernstein is well known for his leadership skills and is an expert in such areas as medical program development, health care integration, medical education and curriculum development, clinical care, clinical research, drug development and clinical trials, and team development.  

Toby Shu, PhD

Department of Surgery, Prince of Wales HospitalThe
Chinese University of Hong Kong
Shatin, New Territories, Hong Kong SAR

Mr. Shu Jie has a PhD in Surgery of The Chinese University of Hong Kong with special interest in functional mitral regurgitation and his current ongoing study has been invested in the cross discipline of machine learning and mitral regurgitation.

Mr. Shu Jie received the Master Degree of Medicine in Cardiac Surgery, Prof. Luo in Changsha Central South University and the Bachelor Degree of Medicine in Clinical Laboratory in Central South University, Xiangya School of Medicine.

Chen Xin, PhD Public Health

Associate Professor, School of Health Law
Université Paris Cité

Dr. Chen Xin is currently the deputy dean of College of Public Health of Shanghai University of Medicine and Health Sciences, the director of China-Europe Cooperation and Exchange Center of Shanghai University of Medicine and Health Sciences, and the secretary of the academic committee of Shanghai General Practice Education and Research Center. Dr. Xin Chen, is a Ph.D. in Public Health, Associate Professor of School of Health Law, Université Paris Cité, member of the Public Health Incident Evaluation Committee of ANSM, France. His research direction is public health policy research.

Wang Ling, MD

Deputy Chief Physician

Wang Ling, MD, deputy chief physician, has been engaged in clinical work of infectious diseases for more than 20 years, completed postdoctoral research in Japan, and supported poverty-stricken mountainous areas in western Hunan and Pingkuang Hospital in Jiangxi Province.

She was responsible for the specific work of fever clinic during the worst SARS and H1N1 epidemics, and diagnosed and cured various severe liver diseases, ascites due to liver cirrhosis, meningitis, diarrhea and various febrile diseases.She has won Hunan Science and Technology Progress Award and Hunan Medical and Health Science and Technology Progress Award. At present, she is the backbone of the major scientific and technological projects of the Ministry of Health, and has participated in many research projects, and participated in 3 medical monographs.

Professor Teerha Piratvisuth

Professor of Medicine
Prince of Songkla University
Hat Yai, Thailand

Dr Teerha Piratvisuth is Professor of Medicine at the Prince of Songkla University, Hat Yai, Thailand. He completed his medical degree with first class honor, at the Prince of Songkla University in 1985. During 1993–94 he studied as a Clinical Fellow in hepatology at King’s College School of Medicine and Dentistry in London, UK. In 1995 he moved to the US, where he spent a further year as a Clinical Fellow in hepatology and endoscopy at the University Texas, Houston Medical School. He also currently holds the positions of Vice Dean at Prince of Songkla University and Director of the NKC Institute of Gastroenterology and Hepatology. Dr Piratvisuth was a President of the Liver Society of Thailand during 2011-2012. He is a President of APASL 2011, a Vice President of APDW 2012, Scientific Committee Chairman of APLD 2016, Scientific Committee Chairman of Gastro 2018 and Honorary President APASL 2021. Dr Piratvisuth is a member of the steering committee of APASL. Dr Piratvisuth has an extensive publication history on liver disease particularly hepatitis B&C and is on the editorial board of Hepatology International, Korean Journal of Gastroenterology and Chinese Journal of Infectious Disease and is a reviewer for the Journal of Gastroenterology and Hepatology, the Journal of Alimentary Pharmacology and Therapeutics, the Journal of Hepatology, Hepatology, Liver International, Hepatology International, the Journal of Viral Hepatitis, Antiviral Therapy and Journal of Antimicrobial chemotherapy.

Professor Phunchai Charatcharoenwitthaya

Professor Faculty of Medicine
Siriraj Hospital, Mahidol University
Bangkok, Thailand

Phunchai Charatcharoenwitthaya is Professor Faculty of Medicine Siriraj Hospital, Mahidol University. Dr. Charatcharoenwitthaya’s interests include nonalcoholic fatty liver disease (NAFLD), chronic viral hepatitis, cholestatic liver diseases in adults, as well as cirrhosis with complications. The primary focus of his research is on clinical trials and means of optimizing the medical management of patients with these disorders.

Additionally, he has served on numerous committees for the Thai Association for the Study of the Liver as well as the Gastroenterological Association of Thailand. Dr. Charatcharoenwitthaya served as the associate editor for the Frontiers in Medicine and was previously the associate editor for the BMC Gastroenterology. He is on the editorial board of the Journal of Clinical and Translational Hepatology. He completed his clinical research fellowship in Gastroenterology and Hepatology at Mayo Clinic (Rochester, USA).

Technology Required to Participate

All ECHO HBV modules will be conducted on the Zoom platform for “face-to-face” interaction. We can’t wait to see you!​

To use Zoom, you must have a PC, tablet or laptop that has a camera, microphone and speakers. You also will need a robust Internet connection.

Click here to download ZOOM

Zoom Participant Guide

Zoom FAQ